Table 1.
Patient characteristics between the training cohort and test cohort
| Characteristic | Training cohort | Test cohort | p value |
|---|---|---|---|
| Number of patients | 364 | 102 | / |
| Number of malignant tumors | 317 (87.1%) | 92 (90.2%) | .40 |
| Age (year)† | 54.6 ± 12.2 | 54.4 ± 12.1 | .59 |
| Number of men/women | 281/83 | 72/30 | .17 |
| ALT (U/L)‡ | 24 (17–38) | 28 (17–39.5) | .42 |
| AST (U/L)‡ | 24.5 (20–35) | 25 (20–35.5) | .71 |
| ALB (g/L)‡ | 42 (39–45) | 43.5 (40–47) | .09 |
| GGT (U/L)‡ | 48 (27.3–81.8) | 39.5 (23–94.3) | .37 |
| PLT (× 109/L)‡ | 167 (121–226) | 156.5 (108.8–197.3) | .11 |
| INR† | 0.98 (0.9–1.0) | 1 (0.95–1.06) | .10 |
| Total bile acid (μmol/L)‡ | 6.9 (4.1–11.4) | 6.4 (3.4–10.8) | .73 |
| Total cholesterol (mg/dl)‡ | 4 (3.6–4.6) | 4 (3.4–4.4) | .24 |
| Fibrosis stages | .99 | ||
| S0 | 79 | 20 | |
| S1 | 42 | 13 | |
| S2 | 53 | 15 | |
| S3 | 43 | 13 | |
| S4 | 147 | 41 | |
†Data are mean ± standard deviation
‡Data are the median, with the interquartile range in parentheses
ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, GGT gamma-glutamyl transpeptidase, PLT platelet count, INR international normalized ratio